57676-49-0

Basic information

• Product Name: 2-(4-METHOXYPHENYL)ACETOHYDRAZIDE
• Synonyms: 4-METHOXYPHENYLACETOHYDRAZIDE;(4-METHOXY-PHENYL)-ACETIC ACID HYDRAZIDE;AKOS B014950;2-(4-METHOXYPHENYL)ACETOHYDRAZIDE;CHEMBRDG-BB 3014950;ASISCHEM U29774;ART-CHEM-BB B014950;2-(4-methoxyphenyl)acetohydrazide(SALTDATA: FREE)
• CAS NO: 57676-49-0
• Molecular Formula: C₉H₁₂N₂O₂
• Molecular Weight: 180.2
• Mol File: 57676-49-0.mol
• Article Data: 23

Chemical Properties

• Boiling Point: 403.1 °C at 760 mmHg
• Flash Point: 197.6 °C
• Appearance: /
• Density: 1.156g/cm³
• Vapor Pressure: 1.04E-06mmHg at 25°C
• Refractive Index: 1.549
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 2-(4-METHOXYPHENYL)ACETOHYDRAZIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-METHOXYPHENYL)ACETOHYDRAZIDE(57676-49-0)
• EPA Substance Registry System: 2-(4-METHOXYPHENYL)ACETOHYDRAZIDE(57676-49-0)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22
• HazardClass: IRRITANT
• Hazardous Substances Data: 57676-49-0(Hazardous Substances Data)

Usage

General Description

2-(4-Methoxyphenyl)acetohydrazide is a chemical compound with the chemical formula C10H14N2O2. It is an organic compound that belongs to the class of hydrazides and is commonly used in organic synthesis and pharmaceutical research. The compound is a white to off-white crystalline powder that is sparingly soluble in water but soluble in organic solvents. It is often used as a reagent in the synthesis of various pharmaceutical compounds and as a building block in the production of other organic molecules. It also has potential applications in medicinal chemistry, particularly in the development of new drugs for various therapeutic uses.

InChI:InChI=1/C9H12N2O2/c1-13-8-4-2-7(3-5-8)6-9(12)11-10/h2-5H,6,10H2,1H3,(H,11,12)

Upstream product

• 23786-14-3 4-methoxy-phenyl acetic acid methyl ester 
• 4693-91-8 4-methoxyphenyl-acetic chloride 
• 14062-18-1 ethyl p-methoxyphenylacetate 
• 104-01-8 4-Methoxyphenylacetic acid 

Downstream Products

• 34546-99-1 5-(4-methoxy-benzyl)-3H-[1,3,4]oxadiazol-2-one 
• 57676-21-8 5,5'-bis-(4-methoxy-benzyl)-2,3,2',3'-tetrahydro-3,3'-(2-oxa-propane-1,3-diyl)-bis-[1,3,4]oxadiazole 
• 541533-57-7 (4-Methoxy-phenyl)-acetic acid [1-(2-chloro-phenyl)-eth-(E)-ylidene]-hydrazide 
• 349645-63-2 (4-Methoxy-phenyl)-acetic acid [1-(2-chloro-phenyl)-meth-(E)-ylidene]-hydrazide 
• 84319-36-8 (4-Methoxy-phenyl)-acetic acid [1-phenyl-meth-(E)-ylidene]-hydrazide 
• 93073-37-1 5-(4-methoxybenzyl)-1,3,4-oxadiazole-2(3H)-thione 
• 385366-48-3 (4-methoxy-phenyl)-acetic acid N'-(4-phenyl-4,5,6,7-tetrahydro-3H-[1,4]diazepin-2-yl)-hydrazide 
• 302949-15-1 2-[5-(4-methoxy-benzyl)-[1,3,4]oxadiazol-2-ylsulfanyl]-1-phenyl-ethanone 
• 302949-11-7 1-(4-bromo-phenyl)-2-[5-(4-methoxy-benzyl)-[1,3,4]oxadiazol-2-ylsulfanyl]-ethanone 
• 126381-23-5 5-(4-Methoxy-benzyl)-4-(4-methoxy-phenyl)-2,4-dihydro-[1,2,4]triazol-3-one 

Relevant articles and documents

Synthesis and structure-activity relationships of 3,4,5-trisubstituted-1,2,4-triazoles: High affinity and selective somatostatin receptor-4 agonists for Alzheimer's disease treatment

Somatostatin receptor-4 (SST4) is highly expressed in brain regions affiliated with learning and memory. SST4 agonist treatment may act to mitigate Alzheimer's disease (AD) pathology. An integrated approach to SST4 agonist lead optimization is presented herein. High affinity and selective agonists with biological efficacy were identified through iterative cycles of a structure-based design strategy encompassing computational methods, chemistry, and preclinical pharmacology. 1,2,4-Triazole derivatives of our previously reported hit (4) showed enhanced SST4 binding affinity, activity, and selectivity. Thirty-five compounds showed low nanomolar range SST4 binding affinity, 12 having a Ki 500-fold affinity for SST4 as compared to SST2A. SST4 activities were consistent with the respective SST4 binding affinities (EC50 600-fold selectivity over SST2A) display a favorable physiochemical profile, and was advanced to learning and memory behavior evaluations in the senescence accelerated mouse-prone 8 model of AD-related cognitive decline. Chronic administration enhanced learning with i.p. dosing (1 mg kg-1) compared to vehicle. Chronic administration enhanced memory with both i.p. (0.01, 0.1, 1 mg kg-1) and oral (0.01, 10 mg kg-1) dosing compared to vehicle. This study identified a novel series of SST4 agonists with high affinity, selectivity, and biological activity that may be useful in the treatment of AD. This journal is

Novel 1,3,4-oxadiazole Compound and Pharmaceutical Composition For Lowering Blood Glucose Comprising The Same

The present invention provides a 1,3,4-oxadiazole compound represented by chemical formula 1 or a pharmaceutically acceptable salt thereof, wherein in chemical formula 1, the R is a methoxy group, the X is a hydrogen, methoxy or fluoro group, and the n an

Microwave-Assisted Synthesis, In Vivo Anti-Inflammatory and In Vitro Anti-Oxidant Activities, and Molecular Docking Study of New Substituted Schiff Base Derivatives

In view of considerable interest in the design and synthesis of new heterocyclic compounds with promising biological activities for medical and biological applications, a series of eight imine derivatives have been synthesized through microwave-assisted S